You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1799 Results
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Apr 2022
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Aug 2019
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Jun 2021
Regimen
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2017
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    lomustine
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Ramucirumab - Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Mar 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Oct 2017

Pages